Skip to main content

previous disabled Page of 3
and
  1. Article

    Open Access

    Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL

    In the phase 3 RESONATE study, ibrutinib demonstrated superior progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) compared with ofatumumab in relapsed/refractory CLL patient...

    J R Brown, P Hillmen, S O’Brien, J C Barrientos, N M Reddy, S E Coutre, C S Tam in Leukemia (2018)

  2. No Access

    Article

    The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia

    Recurrent chromosomal abnormalities and gene mutations detected at the time of diagnosis of acute myeloid leukemia (AML) are associated with particular disease features, treatment response and survival of AML ...

    A-K Eisfeld, K Mrózek, J Kohlschmidt, D Nicolet, S Orwick, C J Walker in Leukemia (2017)

  3. No Access

    Article

    PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment

    D Jones, J A Woyach, W Zhao, S Caruthers, H Tu, J Coleman, J C Byrd in Leukemia (2017)

  4. No Access

    Article

    Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia

    The clinical course of patients with recently diagnosed early stage chronic lymphocytic leukemia (CLL) is highly variable. We examined the relationship between CLL-cell birth rate and treatment-free survival (...

    E J Murphy, D S Neuberg, L Z Rassenti, G Hayes, R Redd, C Emson, K Li in Leukemia (2017)

  5. No Access

    Article

    Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia

    Core-binding factor acute myeloid leukemia (CBF-AML) is defined by the presence of either t(8;21)(q22;q22)/RUNX1-RUNX1T1 or inv(16)(p13.1q22)/t(16;16)(p13.1;q22)/CBFB-MYH11. The resulting fusion genes require a ‘...

    A-K Eisfeld, J Kohlschmidt, S Schwind, D Nicolet, J S Blachly, S Orwick, C Shah in Leukemia (2017)

  6. Article

    Open Access

    Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study

    M Montillo, S O'Brien, A Tedeschi, J C Byrd, C Dearden, D Gill in Blood Cancer Journal (2017)

  7. No Access

    Article

    Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies

    The nuclear export receptor, Exportin 1 (XPO1), mediates transport of growth-regulatory proteins, including tumor suppressors, and is overactive in many cancers, including chronic lymphocytic leukemia (CLL), a...

    Z A Hing, H Y J Fung, P Ranganathan, S Mitchell, D El-Gamal, J A Woyach in Leukemia (2016)

  8. No Access

    Article

    Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2

    A-K Eisfeld, J Kohlschmidt, K Mrózek, J S Blachly, D Nicolet, K Kroll, S Orwick in Leukemia (2016)

  9. No Access

    Article

    Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3)

    B Bhatnagar, J S Blachly, J Kohlschmidt, A-K Eisfeld, S Volinia, D Nicolet in Leukemia (2016)

  10. No Access

    Article

    Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia

    Chronic lymphocytic leukemia (CLL) is frequently complicated by secondary autoimmune cytopenias (AICs). Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase approved for the treatment of relapsed...

    K A Rogers, A S Ruppert, A Bingman, L A Andritsos, F T Awan, K A Blum in Leukemia (2016)

  11. No Access

    Article

    Autologous hematopoietic stem cell transplant induces the molecular aging of T-cells in multiple myeloma

    A Rosko, C Hofmeister, D Benson, Y Efebera, Y Huang in Bone Marrow Transplantation (2015)

  12. No Access

    Article

    Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia

    Dinaciclib (SCH727965) is a selective CDKi chosen for clinical development based upon a favorable therapeutic index in cancer xenograft models. We performed a phase I dose escalation study of dinaciclib in rel...

    J Flynn, J Jones, A J Johnson, L Andritsos, K Maddocks, S Jaglowski, J Hessler in Leukemia (2015)

  13. No Access

    Article

    miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton’s tyrosine kinase inhibition with Ibrutinib

    D Guinn, A S Ruppert, K Maddocks, S Jaglowski, A Gordon, T S Lin, R Larson in Leukemia (2015)

  14. No Access

    Article

    Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia

    Selective cytotoxicity to cancer cells without compromising their normal counterparts pose a huge challenge for traditional drug design. Here we developed a tumor antigen-targeted delivery of immunonanoparticl...

    R Mani, Y Mao, F W Frissora, C-L Chiang, J Wang, Y Zhao, Y Wu, B Yu, R Yan in Leukemia (2015)

  15. No Access

    Article

    Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response

    W E Pierceall, S L Warner, R J Lena, C Doykan, N Blake, M Elashoff, D V Hoff in Leukemia (2014)

  16. No Access

    Article

    Circulating miRNA markers show promise as new prognosticators for multiple myeloma

    A Rocci, C C Hofmeister, S Geyer, A Stiff, M Gambella, L Cascione, J Guan in Leukemia (2014)

  17. No Access

    Article

    The CD37-targeted antibody–drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model

    Therapeutic regimens for chronic lymphocytic leukemia (CLL) have increasingly utilized monoclonal antibodies since the chimeric anti-CD20 antibody rituximab was introduced. Despite improved clinical outcomes, ...

    K A Beckwith, F W Frissora, M R Stefanovski, W H Towns, C Cheney, X Mo in Leukemia (2014)

  18. No Access

    Article

    Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center

    D M Stephens, A S Ruppert, J A Jones, J Woyach, K Maddocks, S M Jaglowski in Leukemia (2014)

  19. No Access

    Article

    Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells

    Y Zhong, D El-Gamal, J A Dubovsky, K A Beckwith, B K Harrington, K E Williams in Leukemia (2014)

  20. No Access

    Article

    Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia

    Histone deacetylase (HDAC) inhibitors either alone or in combination with hypomethylating agents have limited clinical effect in acute myeloid leukemia (AML). Previously, we demonstrated that AML patients with...

    A Mims, A R Walker, X Huang, J Sun, H Wang, R Santhanam, A M Dorrance, C Walker in Leukemia (2013)

previous disabled Page of 3